EPISODE · Dec 18, 2025 · 2 MIN
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
from Applied Clinical Trials · host Applied Clinical Trials
In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s twice-yearly biologic for severe asthma, and examine a national priority voucher granted for a new multiple myeloma treatment combination.
Embed this episode
Ready to play
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
0:00
2:14
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Applied Clinical Trials?
This episode is 2 minutes long.
When was this Applied Clinical Trials episode published?
This episode was published on December 18, 2025.
Can I download this Applied Clinical Trials episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!